Bayer to begin Phase III with riociguat
This article was originally published in Scrip
Executive Summary
Bayer Schering Pharma have been given the go-ahead to initiate its Phase III programme for its first-in-class vasodilator riociguat (BAY 63-2521) in the potential indications of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).